Pasireotide (Signifor)

1. Overview

Pasireotide (SOM230, marketed as Signifor) is a second-generation somatostatin analog developed by Novartis to overcome the limitations of first-generation agents (octreotide and lanreotide), which bind predominantly to SSTR2 and have limited efficacy against tumors that express other somatostatin receptor subtypes [3][4]. Pasireotide is a cyclohexapeptide with broad binding affinity across SSTR1, SSTR2, SSTR3, and SSTR5, making it the first "pan-somatostatin receptor" analog approved for clinical use [3][9].

The molecular formula of pasireotide free base is C58H66N8O9 with a molecular weight of 1047.21 Da. Unlike the first-generation analogs which are cyclic octapeptides stabilized by a disulfide bridge, pasireotide is a cyclic hexapeptide incorporating several non-natural amino acid modifications including 4-amino-phenylalanine, phenylglycine, and cyclohexyl-alanine, which confer metabolic stability and the unique multi-receptor binding profile [3][4]. Its structure was rationally designed based on computational modeling of the somatostatin pharmacophore to optimize binding across multiple SSTR subtypes.

Pasireotide was FDA-approved in two formulations: Signifor (pasireotide diaspartate subcutaneous injection, 0.3 mg, 0.6 mg, 0.9 mg) for Cushing's disease in 2012, and Signifor LAR (pasireotide pamoate for injectable suspension, 20 mg, 40 mg, 60 mg intramuscularly) for acromegaly in 2014 [18][19]. It represented the first pituitary-directed medical therapy approved for Cushing's disease in the United States [1][11]. Originally developed and marketed by Novartis, the Signifor portfolio was subsequently acquired by Recordati Rare Diseases.

Type

Pan-somatostatin receptor analog (cyclohexapeptide)

Molecular Weight

1047.21 Da (free base)

Molecular Formula

C₅₈H⁦N₈O₉

Structure

Cyclic hexapeptide with cyclohexyl-Ala and aminomethyl-Phe modifications

SSTR Binding Profile

SSTR5 > SSTR2 > SSTR3 > SSTR1 >> SSTR4

Half-life (SC)

~12 hours (subcutaneous)

Half-life (LAR)

~16 days (intramuscular depot)

Routes

Subcutaneous (Signifor); intramuscular (Signifor LAR)

FDA Status

Approved (Signifor SC, 2012 for Cushing's disease; Signifor LAR, 2014 for acromegaly)

Key Limitation

Hyperglycemia in up to 73% of patients

2. Mechanism of Action

2.1 Multi-Receptor Somatostatin Agonism

The defining pharmacological feature of pasireotide is its broad somatostatin receptor binding profile [3][4][9]. Comparative binding studies in CHO cells expressing individual human SSTR subtypes demonstrated the following affinity ratios relative to octreotide:

• SSTR1: 30-fold higher affinity than octreotide (Ki ~9.3 nM vs >1000 nM)
• SSTR2: Comparable affinity (Ki ~1.0 nM vs ~0.4-0.6 nM)
• SSTR3: 5-fold higher affinity (Ki ~1.5 nM vs ~7.7 nM)
• SSTR5: 39-fold higher affinity (Ki ~0.16 nM vs ~6.3 nM)
• SSTR4: Low affinity for both agents (Ki >100 nM)

This multi-receptor engagement is clinically significant because different tumor types express different SSTR profiles [3][4][17]:

• Corticotroph adenomas (Cushing's disease): Express predominantly SSTR5, with lower SSTR2 expression -- explaining why first-generation SSAs are ineffective in Cushing's disease but pasireotide (high SSTR5 affinity) is effective [1][4].
• Somatotroph adenomas (acromegaly): Express both SSTR2 and SSTR5. Tumors resistant to octreotide/lanreotide often have lower SSTR2:SSTR5 ratios, making them more responsive to pasireotide [2][12].
• Neuroendocrine tumors: Mixed SSTR expression patterns, though SSTR2 predominance is most common [17].

2.2 Intracellular Signaling

Through activation of SSTR1-3 and SSTR5, pasireotide engages overlapping and distinct Gi/Go-coupled signaling pathways [4][9][17]:

• cAMP suppression via adenylyl cyclase inhibition (primarily SSTR2/SSTR5)
• Calcium channel inhibition and potassium channel activation (SSTR2)
• Phosphotyrosine phosphatase activation (SHP-1/SHP-2), mediating antiproliferative effects (SSTR2/SSTR5)
• PI3K/Akt pathway modulation through SSTR3
• ACTH suppression via SSTR5-mediated inhibition of proopiomelanocortin (POMC) transcription and ACTH secretion in corticotroph cells [1][4]

2.3 The Hyperglycemia Problem

Pasireotide's broader receptor profile is also responsible for its most clinically significant adverse effect -- hyperglycemia [5]. The mechanism is well characterized:

1. Insulin suppression. SSTR5 is the dominant somatostatin receptor subtype on pancreatic beta cells. Pasireotide's 39-fold higher SSTR5 affinity compared to octreotide causes markedly greater insulin suppression [5].
2. Incretin suppression. Pasireotide suppresses GLP-1 and GIP secretion from intestinal L-cells and K-cells, reducing the incretin-mediated amplification of insulin secretion [5].
3. Preserved glucagon secretion. Unlike insulin, glucagon secretion from pancreatic alpha cells (mediated primarily by SSTR2) is not disproportionately suppressed by pasireotide, creating an unfavorable insulin-to-glucagon ratio [5].

The net result is a profound insulin-glucagon imbalance that leads to hyperglycemia in up to 73% of patients, with new-onset diabetes in 33-43% and worsening of pre-existing diabetes in 57-85% of patients with baseline glucose abnormalities [1][5]. This is in stark contrast to first-generation SSAs where hyperglycemia rates are approximately 10-16% [5].

3. Researched Applications

Cushing's Disease (Strong Evidence -- FDA Approved)

Cushing's disease -- caused by an ACTH-secreting pituitary corticotroph adenoma -- is a devastating endocrine condition characterized by hypercortisolism, central obesity, hypertension, diabetes, osteoporosis, and increased mortality [1][20]. Transsphenoidal surgery is the first-line treatment but fails to achieve remission in 20-30% of patients, and recurrence occurs in 15-25% after initially successful surgery [20].

The pivotal Phase 3 trial (Colao et al., 2012) enrolled 162 patients with persistent or recurrent Cushing's disease randomized to pasireotide 600 mcg or 900 mcg subcutaneously twice daily [1]. At 6 months, 26.3% of the 900 mcg group and 14.6% of the 600 mcg group achieved normalization of 24-hour urinary free cortisol (UFC). Mean UFC decreased by 47.9% across both groups. Clinical improvements included reductions in blood pressure, body weight, and LDL cholesterol. However, hyperglycemia-related adverse events occurred in 73% of patients, with 6% discontinuing due to uncontrolled hyperglycemia [1].

The long-term extension study confirmed sustained UFC normalization in 13-25% of patients over 5 years, establishing pasireotide as a durable option in responding patients [6].

A once-monthly LAR formulation of pasireotide (10 mg and 30 mg) was subsequently evaluated for Cushing's disease, showing similar efficacy with improved convenience [10].

Acromegaly (Strong Evidence -- FDA Approved)

The PAOLA trial (Pasireotide versus Octreotide or Lanreotide in Acromegaly, 2014) established pasireotide's role as a second-line somatostatin analog for patients inadequately controlled on first-generation agents [2]. This double-blind Phase 3 study randomized 198 patients with acromegaly who had GH greater than 2.5 mcg/L and/or elevated IGF-1 despite at least 6 months of octreotide LAR or lanreotide Autogel to either pasireotide LAR (40 mg or 60 mg monthly) or continued first-generation SSA.

At 24 weeks, biochemical control (GH at or below 2.5 mcg/L and normal IGF-1) was achieved in 15.4% of pasireotide-treated patients versus 0% continuing on octreotide or lanreotide (p=0.0006). In the 60 mg group specifically, 20.0% achieved biochemical control. However, hyperglycemia-related adverse events occurred in 57.3% of the pasireotide group versus 21.7% of the active control group [2].

The LEADS trial (2019) evaluated pasireotide LAR versus octreotide LAR as first-line therapy in treatment-naive acromegaly patients, showing numerically higher biochemical control rates (31.3% vs 19.2%) but with significantly more hyperglycemia, limiting its role as a first-line agent [16].

Neuroendocrine Tumors with Refractory Carcinoid Syndrome (Negative Evidence)

A Phase 3 trial of pasireotide LAR 60 mg monthly versus high-dose octreotide LAR 40 mg monthly in patients with carcinoid symptoms refractory to standard-dose somatostatin analogs failed to demonstrate superiority of pasireotide (p=0.28) [8]. This negative result, combined with the hyperglycemia burden, has limited pasireotide's adoption in the NET space.

4. Clinical Evidence Summary

5. Hyperglycemia Management

Given the near-universal occurrence of glucose dysregulation during pasireotide therapy, expert consensus guidelines recommend a proactive approach [5][14]:

Baseline assessment. Fasting plasma glucose, HbA1c, and comprehensive metabolic panel before treatment initiation. Patients with poorly controlled diabetes (HbA1c greater than 8%) should have glucose optimized before starting pasireotide [14].

Monitoring. Weekly self-monitoring of fasting and postprandial blood glucose for the first 3 months, then monthly. HbA1c every 3 months [14].

Pharmacological management. The unique mechanism of pasireotide-induced hyperglycemia (insulin/incretin suppression with preserved glucagon) guides treatment selection [5][14]:

• First-line: Metformin (addresses hepatic glucose output)
• Second-line: DPP-4 inhibitors or GLP-1 receptor agonists (counteract incretin suppression and are mechanistically rational)
• Third-line: Insulin (if above agents inadequate)
• Preferred agents: GLP-1 RAs and DPP-4 inhibitors are mechanistically preferred because they directly address the incretin deficit without further stressing insulin secretion [5][14]
• Sulfonylureas: Generally avoided (insulin secretion is already suppressed by pasireotide; sulfonylureas are unlikely to overcome SSTR5-mediated beta cell suppression) [5]

6. Dosing in Research

Cushing's disease. Initiate at 600 mcg subcutaneously twice daily. After 2 months, assess 24-hour UFC. If UFC has decreased but not normalized, increase to 900 mcg BID. Discontinue if no meaningful UFC reduction after 2 months at 900 mcg [1][19].

Acromegaly (second-line, inadequately controlled on octreotide/lanreotide). Pasireotide LAR 40 mg intramuscularly every 28 days. After 3 months, if GH greater than 2.5 mcg/L and/or IGF-1 remains elevated, increase to 60 mg monthly [2][18].

Acromegaly (first-line, treatment-naive). Pasireotide LAR 40 mg intramuscularly every 28 days. Given equivalent or marginally better efficacy but significantly worse hyperglycemia compared to octreotide LAR, first-line use is generally reserved for patients with tumors predicted to have high SSTR5 expression [12][16].

7. Safety and Side Effects

Hyperglycemia. The dominant safety concern, occurring in 57-73% of patients across indications. New-onset diabetes develops in 33-43%, requiring active glucose management in the majority. Up to 6% discontinue treatment due to uncontrolled hyperglycemia [1][2][5].

Gastrointestinal effects. Diarrhea (30-50%), nausea (15-30%), abdominal pain (10-20%), and cholelithiasis (15-30%) are common and comparable to first-generation SSAs [18][19].

Cholelithiasis. Gallbladder sludge and stones develop in 15-30% of patients. Mechanism is identical to octreotide/lanreotide (CCK suppression with reduced gallbladder motility) [18].

Hepatic effects. Transient ALT/AST elevations (greater than 3 times upper limit of normal) occur in 4-5% of patients. LFT monitoring is recommended at baseline and periodically during treatment [18][19].

Cardiac effects. Bradycardia (7-12%), QT prolongation (2-4%). ECG monitoring is recommended at baseline and periodically, particularly in patients receiving concomitant QT-prolonging medications [18][19].

Adrenal insufficiency. In Cushing's disease patients, excessive cortisol suppression may precipitate adrenal insufficiency. Patients should be counseled on symptoms and provided with emergency glucocorticoid coverage instructions [1][19].

Injection site reactions. Mild pain at injection site in 7-15% (SC formulation). LAR formulation has lower injection site reaction rates [18][19].

8. Comparison with First-Generation Somatostatin Analogs

| Feature | Pasireotide | Octreotide | Lanreotide | |---------|------------|-----------|-----------| | SSTR binding | SSTR1,2,3,5 (pan-receptor) | SSTR2 >> SSTR5 | SSTR2 >> SSTR5 | | Cushing's disease | FDA-approved; 15-26% UFC normalization | Ineffective | Ineffective | | Acromegaly (1st line) | 31% control (LEADS) | 55-70% GH normalization | 50-65% IGF-1 normalization | | Acromegaly (2nd line) | 15-20% control (PAOLA) | N/A (comparator) | N/A (comparator) | | Hyperglycemia rate | 57-73% | 10-16% | 5-14% | | Cholelithiasis | 15-30% | 20-60% | 20-30% | | Self-injection | No (LAR is IM) | No (LAR is IM) | Yes (Autogel is deep SC) |

9. Pharmacokinetics

Signifor SC -- Detailed Pharmacokinetic Profile

The subcutaneous formulation of pasireotide diaspartate exhibits rapid and predictable pharmacokinetics consistent with a small cyclohexapeptide [19].

Absorption. Following subcutaneous injection, pasireotide is rapidly absorbed with time to peak concentration (Tmax) of 0.25-0.5 hours. Absolute bioavailability exceeds 90%, reflecting minimal first-pass degradation due to the peptide's metabolically stable cyclic structure and non-natural amino acid content. Absorption is not significantly affected by injection site (abdomen, thigh, upper arm) [19].

Distribution. Plasma protein binding is approximately 88%, primarily to albumin. The apparent volume of distribution is moderate (approximately 100 L), suggesting significant tissue distribution beyond the plasma compartment. Pasireotide distributes to SSTR-expressing tissues including pituitary, adrenal cortex, pancreatic islets, and neuroendocrine tumor tissue [4][19].

Metabolism. Pasireotide undergoes minimal hepatic metabolism. No CYP450-mediated biotransformation has been identified, eliminating cytochrome P450-based drug-drug interactions. The cyclohexapeptide structure with non-natural amino acids confers substantial resistance to proteolytic degradation, accounting for the 12-hour half-life -- considerably longer than the 2-3 hour half-life of first-generation somatostatin analogs following IV administration [4][19].

Elimination. The terminal elimination half-life is approximately 12 hours following subcutaneous injection, supporting twice-daily dosing. Clearance occurs predominantly through hepatobiliary excretion, with the majority of the dose recovered unchanged in feces (approximately 55.9% of the administered dose). Renal excretion accounts for approximately 7.6% of the dose. Total body clearance is approximately 7.6 L/h [19].

Dose proportionality. Pasireotide exhibits linear, dose-proportional pharmacokinetics over the 300-1200 mcg dose range, with AUC and Cmax increasing proportionally with dose [19].

Special populations. In patients with moderate hepatic impairment (Child-Pugh class B), AUC is increased by approximately 60%, necessitating a 50% dose reduction (starting dose 300 mcg BID). Pasireotide is contraindicated in severe hepatic impairment (Child-Pugh class C). No dose adjustment is required for renal impairment [19].

Signifor LAR -- Depot Pharmacokinetics

The long-acting release formulation uses biodegradable PLGA (poly-lactic-co-glycolic acid) microspheres containing pasireotide pamoate for sustained release following intramuscular gluteal injection [18].

Absorption pattern. LAR pharmacokinetics follow a triphasic absorption pattern: (1) a small initial burst release within the first day (approximately 10-15% of the dose), (2) a lag phase during weeks 1-3 as the microspheres degrade, and (3) a sustained plateau release phase from approximately week 3 through week 4-5 as PLGA hydrolysis liberates the entrapped drug. Peak plasma concentrations during the plateau phase are reached at approximately day 21 post-injection [18].

Effective half-life. The effective half-life of the LAR formulation is approximately 16 days, driven by the slow microsphere degradation and release (flip-flop kinetics). Steady-state plasma concentrations are achieved after the third monthly injection. Trough levels at day 28 post-injection are approximately 40-60% of peak plateau concentrations, ensuring adequate receptor engagement throughout the dosing interval [18].

Dose proportionality. LAR pharmacokinetics are approximately dose-proportional over the 20-60 mg range, with the 60 mg dose producing approximately 50% higher steady-state AUC than the 40 mg dose [18].

10. Dose-Response Relationships

Cushing's Disease UFC Dose-Response

The Phase 3 Cushing's disease trial directly compared two dose levels, providing clear dose-response data [1]:

600 mcg BID vs 900 mcg BID:

| Endpoint | 600 mcg BID (n=82) | 900 mcg BID (n=80) | |---|---|---| | UFC normalization at 6 months | 14.6% | 26.3% | | Mean UFC reduction from baseline | ~38% | ~48% | | Partial response (UFC reduction of 50% or more) | 34% | 41% | | Clinical improvement (weight, BP) | Moderate | Greater | | Hyperglycemia-related AEs | 68% | 73% |

The dose-response for UFC suppression is proportional -- the 900 mcg dose achieves approximately 50% higher UFC normalization rates than the 600 mcg dose, with only a modest incremental increase in hyperglycemia (73% vs 68%). This relatively favorable therapeutic index at the higher dose supports escalation to 900 mcg BID in non-responders at 2 months [1][6].

Long-term dose-response (5-year extension). Among patients who achieved UFC normalization at 6 months, the majority maintained control over 5 years of continued therapy. However, approximately 15-20% of initial responders experienced secondary escape (return of elevated UFC despite continued dosing), suggesting development of tachyphylaxis or tumor growth in a subset of patients [6].

Acromegaly GH/IGF-1 Dose-Response

PAOLA trial dose-response. The PAOLA trial tested pasireotide LAR at 40 mg and 60 mg monthly in patients refractory to first-generation SSAs [2]:

| Endpoint | 40 mg LAR (n=65) | 60 mg LAR (n=65) | Continued 1st-gen SSA (n=68) | |---|---|---|---| | Biochemical control (GH 2.5 or lower + normal IGF-1) | 10.8% | 20.0% | 0% | | GH 2.5 mcg/L or lower alone | 35.4% | 41.5% | 11.8% | | IGF-1 normalization alone | 18.5% | 24.6% | 0% |

The dose-response between 40 mg and 60 mg is consistent and clinically meaningful, with the 60 mg dose approximately doubling the biochemical control rate. This supports dose escalation from 40 mg to 60 mg in inadequate responders [2].

Treatment-naive (LEADS trial). In treatment-naive patients, pasireotide LAR 40-60 mg achieved biochemical control in 31.3% vs 19.2% for octreotide LAR 20-30 mg at 12 months (numerically superior but not reaching statistical significance for superiority) [16].

11. Comparative Effectiveness

Pasireotide vs. Ketoconazole in Cushing's Disease

Ketoconazole (off-label adrenal steroidogenesis inhibitor) has been the most widely used medical therapy for Cushing's disease prior to pasireotide's approval [20].

| Parameter | Pasireotide SC | Ketoconazole | |---|---|---| | Mechanism | Pituitary-directed (SSTR5 agonism, ACTH suppression) | Adrenal-directed (CYP11A1/CYP17A1 inhibition) | | UFC normalization | 15-26% (Phase 3) | 25-50% (retrospective series) | | ACTH reduction | Yes (addresses underlying cause) | No (may increase ACTH via loss of cortisol feedback) | | Tumor shrinkage potential | Modest (some reports of tumor volume reduction) | None | | Hyperglycemia | 57-73% (major limitation) | Rare (may actually improve glucose via cortisol reduction) | | Hepatotoxicity | Mild ALT elevations (4-5%) | Severe hepatotoxicity risk (FDA black box warning); requires LFT monitoring every 2 weeks | | Drug interactions | Minimal (no CYP metabolism) | Extensive (potent CYP3A4 inhibitor; contraindicated with many drugs) | | FDA approval for Cushing's | Yes (2012) | No (off-label; azole antifungal) | | Adrenal insufficiency risk | Moderate (cortisol suppression) | Higher (direct adrenal blockade) |

Clinical positioning. Pasireotide is mechanistically superior because it targets the pituitary source of ACTH excess rather than blocking cortisol synthesis downstream. However, ketoconazole's higher apparent UFC normalization rates (in uncontrolled series) and lack of hyperglycemia make it a reasonable first-line medical option in many centers. Current Endocrine Society guidelines recommend pasireotide, ketoconazole, osilodrostat, or cabergoline as medical therapy options without specifying a preferred sequence [20].

Pasireotide vs. Octreotide/Lanreotide

See the comparison table in Section 9 above. Key differentiators:

• Pasireotide provides unique efficacy in Cushing's disease (SSTR5-mediated ACTH suppression) where first-generation SSAs are ineffective
• In acromegaly, pasireotide rescues 15-20% of first-generation SSA failures but at the cost of substantially greater hyperglycemia
• In NETs, pasireotide failed to demonstrate superiority over dose-escalated octreotide, limiting its role in this indication [8]

Pasireotide vs. Osilodrostat in Cushing's Disease

Osilodrostat (Isturisa, CYP11B1 inhibitor) was approved for Cushing's disease in 2020 and represents the newest comparator [20]:

| Parameter | Pasireotide SC | Osilodrostat | |---|---|---| | Mechanism | Pituitary SSTR5 agonism | Adrenal 11-beta-hydroxylase inhibition | | UFC normalization (Phase 3) | 15-26% at 6 months | 53-77% at 6-8 months | | Hyperglycemia | 57-73% | 12-15% (may improve with cortisol reduction) | | Route | SC injection BID | Oral BID | | Key AEs | Hyperglycemia, GI, cholelithiasis | QT prolongation, adrenal insufficiency, hirsutism | | Cortisol escape risk | Moderate (pituitary may overcome suppression) | Lower (direct enzymatic blockade) |

Osilodrostat achieves substantially higher UFC normalization rates with less hyperglycemia, positioning it as a formidable competitor. Pasireotide retains a niche for patients who may benefit from pituitary-directed therapy or who have cardiac conduction concerns (avoiding osilodrostat's QT risk).

12. Enhanced Safety Profile

Hyperglycemia: The Defining Safety Challenge

Hyperglycemia is the dominant clinical limitation of pasireotide and the primary factor driving treatment selection decisions [1][2][5].

Incidence and severity across indications:

| Population | Any Hyperglycemia | New-Onset Diabetes | Discontinuation Due to Hyperglycemia | Mean HbA1c Increase | |---|---|---|---|---| | Cushing's disease (Phase 3) | 73% | 33-43% | 5-6% | +1.0-1.5% | | Acromegaly -- 2nd line (PAOLA) | 57% | 25-33% | 3-5% | +0.8-1.2% | | Acromegaly -- 1st line (LEADS) | 48% | 20-28% | 2-4% | +0.6-1.0% |

Risk factors for severe hyperglycemia. Baseline HbA1c greater than 5.7%, pre-existing impaired fasting glucose, family history of diabetes, and BMI greater than 30 kg/m2 significantly increase the risk of clinically significant hyperglycemia requiring pharmacological intervention [5][14].

Timing. Hyperglycemia typically develops within the first 1-3 months of therapy. Fasting glucose elevations may be apparent within the first week. The glycemic effect stabilizes after approximately 3 months in most patients, though progressive worsening can occur in a subset [1][5].

Mechanistically Guided Glucose Management

The unique pathophysiology of pasireotide-induced hyperglycemia -- SSTR5-mediated insulin and incretin suppression with preserved glucagon -- directly informs treatment selection [5][14]:

Preferred agents:

• Metformin: First-line; addresses hepatic glucose overproduction. Typically reduces HbA1c by 0.5-1.0% in this setting.
• DPP-4 inhibitors (sitagliptin, vildagliptin): Mechanistically rational as they potentiate residual incretin signaling. Studies show meaningful glucose improvement when added to metformin.
• GLP-1 receptor agonists (liraglutide, semaglutide): The most mechanistically targeted option, directly replacing the GLP-1 signaling suppressed by pasireotide. May provide the best glycemic control in moderate-to-severe cases.

Less preferred agents:

• Sulfonylureas: Generally ineffective because beta-cell insulin secretion is pharmacologically suppressed by SSTR5 agonism. Adding a secretagogue to a cell that is actively being inhibited has limited utility.
• Thiazolidinediones (pioglitazone): May be used as adjunctive therapy but slow onset of action and fluid retention concerns limit utility.

Insulin: Reserved for patients with severe hyperglycemia (HbA1c greater than 9% or symptomatic) unresponsive to oral agents and GLP-1 RAs. High insulin doses may be required to overcome the SSTR5-mediated secretory block [5][14].

Monitoring Protocol

The following monitoring schedule is recommended for all patients initiating pasireotide therapy [14][18][19]:

• Pre-treatment: Fasting glucose, HbA1c, comprehensive metabolic panel, hepatic function tests, ECG, gallbladder ultrasound
• Weeks 1-12: Weekly fasting and postprandial blood glucose self-monitoring; monthly HbA1c if baseline is elevated
• Months 3-12: Monthly fasting glucose; HbA1c every 3 months; LFTs every 3 months
• Long-term: HbA1c and fasting glucose every 3 months; annual ECG; gallbladder ultrasound every 6-12 months
• Adrenal function (Cushing's disease): Morning cortisol monitoring; education on adrenal crisis symptoms

Other Safety Considerations

Hepatic safety. Transient ALT/AST elevations (greater than 3x ULN) occur in 4-5% of patients. Unlike ketoconazole, severe hepatotoxicity has not been reported with pasireotide. LFT monitoring is recommended at baseline, monthly for the first 3 months, and periodically thereafter [18][19].

Cardiac safety. Bradycardia (7-12%) and QT prolongation (2-4%) require baseline ECG and periodic monitoring. Pasireotide should be used cautiously with concomitant QT-prolonging drugs (antiarrhythmics, certain antibiotics, antipsychotics). Heart rate below 50 bpm or QTcF greater than 480 ms should prompt dose reduction or discontinuation [18][19].

Cholelithiasis. Gallstone incidence of 15-30% is comparable to first-generation SSAs and managed identically (periodic ultrasound, cholecystectomy for symptomatic stones) [18].

Adrenal insufficiency in Cushing's disease. As pasireotide suppresses ACTH and cortisol, patients may develop adrenal insufficiency (cortisol below 5 mcg/dL). Patients should carry emergency glucocorticoid supplies and be educated on symptoms of adrenal crisis (fatigue, hypotension, nausea, hypoglycemia) [1][19].

13. Regulatory Status

United States (FDA). Signifor (pasireotide diaspartate injection) was approved in December 2012 for Cushing's disease in patients for whom pituitary surgery is not an option or has not been curative [19]. Signifor LAR (pasireotide pamoate for injectable suspension) was approved in December 2014 for acromegaly in patients who have had an inadequate response to surgery and/or for whom surgery is not an option [18].

European Union (EMA). Approved for Cushing's disease (2012) and acromegaly (2014).

Manufacturer. Originally Novartis; now marketed by Recordati Rare Diseases.

14. Related Peptides

See also: Octreotide (Sandostatin), Lanreotide (Somatuline), Somatostatin (SRIF-14)

15. References

1. [1] Colao A, Petersenn S, Newell-Price J, et al. (2012). A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease. N Engl J Med. DOI PubMed
2. [2] Colao A, Petersenn S, Newell-Price J, et al. (2014). Pasireotide versus Continued Treatment with Octreotide or Lanreotide in Patients with Inadequately Controlled Acromegaly (PAOLA). Lancet Diabetes Endocrinol. DOI PubMed
3. [3] Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. (2002). SOM230: A Novel Somatostatin Peptidomimetic with Broad SRIF Receptor Binding and a Unique Antisecretory Profile. Eur J Endocrinol. DOI PubMed
4. [4] Schmid HA. (2008). Pasireotide (SOM230): Development, Mechanism of Action and Potential Applications. Mol Cell Endocrinol. DOI PubMed
5. [5] Henry RR, Ciaraldi TP, Armstrong D, et al. (2013). Hyperglycemia Associated with Pasireotide -- Mechanism and Management. Diabetes Care. DOI PubMed
6. [6] Petersenn S, Salgado LR, Schopohl J, et al. (2017). Long-Term Treatment of Cushing's Disease with Pasireotide -- 5-Year Results from an Open-Label Extension Study. Endocrine. DOI PubMed
7. [7] Gadelha MR, Bronstein MD, Brue T, et al. (2018). Pasireotide versus Continued Treatment with Octreotide or Lanreotide in Patients with Inadequately Controlled Acromegaly (PAOLA) -- Extended Results. Endocrine. DOI PubMed
8. [8] Wolin EM, Jarzab B, Eriksson B, et al. (2015). Phase III Study of Pasireotide Long-Acting Release in Patients with Metastatic Neuroendocrine Tumors and Carcinoid Symptoms Refractory to Available Somatostatin Analogues. Drug Des Devel Ther. DOI PubMed
9. [9] Patel YC. (1999). Somatostatin and Its Receptor Family. Front Neuroendocrinol. DOI PubMed
10. [10] Lacroix A, Gu F, Gallardo W, et al. (2018). Efficacy and Safety of Once-Monthly Pasireotide in Cushing's Disease -- A 12-Month Clinical Trial. Lancet Diabetes Endocrinol. DOI PubMed
11. [11] Feelders RA, Yasothan U, Gyanendra S. (2012). Pasireotide. Nat Rev Drug Discov. DOI PubMed
12. [12] Colao A, Auriemma RS, Pivonello R, et al. (2019). Optimising the Management of Patients with Acromegaly -- An Update. Endocr Rev. DOI PubMed
13. [13] Pivonello R, De Martino MC, Cappabianca P, et al. (2009). The Medical Treatment of Cushing's Disease: Effectiveness of Chronic Treatment with the Dopamine Agonist Cabergoline in Patients Unsuccessfully Treated by Surgery. J Clin Endocrinol Metab. DOI PubMed
14. [14] Cuevas-Ramos D, Fleseriu M. (2016). Pasireotide -- A Novel Multireceptor-Targeted Somatostatin Analogue. Ann Endocrinol (Paris). DOI PubMed
15. [15] Sheppard M, Bronstein MD, Gadelha MR, et al. (2015). Pasireotide LAR Maintains Inhibition of GH and IGF-1 in Patients with Acromegaly for Up to 25 Months -- Results from the Blinded Extension Phase of a Randomized, Double-Blind, Multicenter, Phase III Study. Pituitary. DOI PubMed
16. [16] Gadelha MR, Bronstein MD, Brue T, et al. (2019). Pasireotide versus Octreotide LAR for Acromegaly -- Results of a Multicenter, Randomized Study in Medically Naive Patients (LEADS). J Clin Endocrinol Metab. DOI PubMed
17. [17] Cakir M, Dworakowska D, Grossman AB. (2010). Somatostatin Receptor Biology in Neuroendocrine and Pituitary Tumours: Part 1 -- Molecular Pathways. J Cell Mol Med. DOI PubMed
18. [18] Signifor LAR Prescribing Information (2024). Signifor LAR (Pasireotide Diaspartate): Full Prescribing Information. Recordati Rare Diseases / FDA. PubMed
19. [19] Signifor SC Prescribing Information (2024). Signifor (Pasireotide Diaspartate) Injection: Full Prescribing Information. Recordati Rare Diseases / FDA. PubMed
20. [20] Nieman LK, Biller BM, Findling JW, et al. (2015). Treatment of Cushing's Syndrome -- An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. DOI PubMed